Frontotemporal Dementia Risk Cohort (FTD-RisC): Early biomarker abnormalities in patients with frontotemporal dementia

Frontotemporal Dementia Risk Cohort (FTD-RisC): Early biomarker abnormalities in patients with frontotemporal dementia - FTD-RisC study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON47834

Enrollment

250

Registered

2009-12-28

Start date

2010-02-22

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's disease frontotemporal dementia Pick's disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1) Patients with frontotemporal dementia referred to our referral center and diagnosed with use of International Consensus Criteria. The dementia symptoms have to be mild (clinical dementia rating

Exclusion criteria

Exclusion criteria: 1) Patients with moderate to severe dementia (clinical dementia rating > 1). 2) Persons with a previous stroke or other (neurological) conditions that may affect cognitive functions (brain tumour, multiple sclerosis, use of psycho-active medications). 3) Contra-indication for undergoing MRI (pacemaker or other metal implants, claustrophobia, or unability to lie still for a period of 30 minutes in the MRI scanner).

Design outcomes

Primary

Measure	Time frame
The main study outcome is the difference between persons with presenile dementia (FTD/AD), presymptomatic mutation carriers and controls using structural and functional connectivity MRI measures.	—

Secondary

Measure	Time frame
At baseline and the follow-up examinations we perform neuropsychological assessments. These neuropsychological tests can be correlated to the MRI results. Protein levels in CSF will be compared between patients, presymptomatic carriers and controls. Relatively new techniques, such as proteomics and microRNA sequencing, will be used to identify biomarkers in CSF and blood; these biomarkers will be compared between mutation carriers (presymptomatic versus symptomatic) and healthy controls.	—

Measure

Time frame

At baseline and the follow-up examinations we perform neuropsychological assessments. These neuropsychological tests can be correlated to the MRI results. Protein levels in CSF will be compared between patients, presymptomatic carriers and controls. Relatively new techniques, such as proteomics and microRNA sequencing, will be used to identify biomarkers in CSF and blood; these biomarkers will be compared between mutation carriers (presymptomatic versus symptomatic) and healthy controls.

—

Countries

Netherlands

Outcome results